Laekna (HKG:2105) said it began recruitment for its Phase I multiple-ascending dose study in China for its obesity drug, with the first visit of the first subject completed, according to a filing with the Hong Kong bourse on Wednesday.
LAE102 is a monoclonal antibody targeting ActRIIA, a receptor linked to muscle growth and fat metabolism, and has been shown to increase muscle and reduce fat in pre-clinical tests.
The pharmaceutical's shares were up by about 11% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.